Stuhler G, Walden P
Max-Planck-Institut für Biologie, Abteilung Immungenetik, Tübingen, Germany.
Cancer Immunol Immunother. 1994 Nov;39(5):342-5. doi: 10.1007/BF01519989.
Immunotherapy of cancer could be possible in cases in which competent effector T cells can be induced. Such an approach depends on expression of tumour-specific antigens by the tumour cells and on the availability of sufficient costimulatory support for activation of cytotoxic T lymphocytes. Here, a strategy for helper T cell recruitment for induction of tumour-specific cytotoxic immune responses is presented. Allogenic MHC class II molecules were introduced into tumour cells by cell fusion. These hybrid cells, when injected into mice, induced rejection of an established tumour. The contribution of CD4-expressing helper T cells in the induction phase and of CD8-expressing T cells in the effector phase of the immune response was demonstrated. The approach described could be applicable to cases in which a suitable tumour antigen is present but not identified; it employs regulatory interactions that govern physiological immune responses and is designed to be minimally invasive.
在能够诱导出有功能的效应T细胞的情况下,癌症免疫疗法才有可能实现。这种方法依赖于肿瘤细胞表达肿瘤特异性抗原,以及为激活细胞毒性T淋巴细胞提供足够的共刺激支持。在此,我们提出一种招募辅助性T细胞以诱导肿瘤特异性细胞毒性免疫反应的策略。通过细胞融合将同种异体MHC II类分子导入肿瘤细胞。将这些杂交细胞注射到小鼠体内时,可诱导已形成肿瘤的排斥反应。研究证实了表达CD4的辅助性T细胞在免疫反应诱导阶段以及表达CD8的T细胞在效应阶段所起的作用。所描述的方法可能适用于存在合适的肿瘤抗原但尚未确定的情况;它利用了调控生理免疫反应的调节性相互作用,并且设计为微创性的。